Whittier Trust Co. boosted its holdings in shares of Medidata Solutions Inc (NASDAQ:MDSO) by 4.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,334 shares of the company’s stock after acquiring an additional 1,021 shares during the period. Whittier Trust Co.’s holdings in Medidata Solutions were worth $2,202,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in MDSO. Dimensional Fund Advisors LP raised its position in shares of Medidata Solutions by 55.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 224,308 shares of the company’s stock worth $15,122,000 after acquiring an additional 80,395 shares in the last quarter. Thrivent Financial for Lutherans raised its position in shares of Medidata Solutions by 9.9% in the 4th quarter. Thrivent Financial for Lutherans now owns 15,688 shares of the company’s stock worth $1,058,000 after acquiring an additional 1,408 shares in the last quarter. Legal & General Group Plc raised its position in shares of Medidata Solutions by 7.1% in the 4th quarter. Legal & General Group Plc now owns 61,664 shares of the company’s stock worth $4,158,000 after acquiring an additional 4,077 shares in the last quarter. Amalgamated Bank raised its position in shares of Medidata Solutions by 127.4% in the 4th quarter. Amalgamated Bank now owns 9,075 shares of the company’s stock worth $612,000 after acquiring an additional 5,085 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Medidata Solutions in the 4th quarter worth approximately $46,802,000.
Shares of Medidata Solutions stock traded down $0.03 during midday trading on Friday, hitting $91.36. The company had a trading volume of 745,353 shares, compared to its average volume of 1,061,919. The firm has a 50 day moving average price of $90.91. The company has a quick ratio of 2.57, a current ratio of 2.56 and a debt-to-equity ratio of 0.27. Medidata Solutions Inc has a 52-week low of $60.10 and a 52-week high of $98.60. The firm has a market cap of $5.71 billion, a PE ratio of 95.17, a P/E/G ratio of 6.04 and a beta of 1.23.
In other Medidata Solutions news, Director Robert Taylor sold 3,294 shares of the stock in a transaction on Thursday, June 6th. The stock was sold at an average price of $90.88, for a total transaction of $299,358.72. Following the sale, the director now directly owns 41,757 shares in the company, valued at approximately $3,794,876.16. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 4.70% of the company’s stock.
Several research analysts have recently issued reports on the company. JPMorgan Chase & Co. raised Medidata Solutions from an “underweight” rating to a “neutral” rating in a research report on Wednesday, June 12th. Dougherty & Co downgraded Medidata Solutions from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 1st. Wells Fargo & Co restated a “hold” rating on shares of Medidata Solutions in a research note on Thursday, June 13th. SunTrust Banks upped their price target on Medidata Solutions from $85.00 to $92.25 and gave the stock a “hold” rating in a research note on Thursday, June 13th. Finally, BidaskClub upgraded Medidata Solutions from a “hold” rating to a “buy” rating in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $84.27.
About Medidata Solutions
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development and commercialization of new therapies. The company's platform solutions include data capture and management, and trial planning and management.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.